« Return to News | Drug Sponsors | R&D Trends

Signum, GlaxoSmithKline ink research agreement

Thursday, November 10, 2011 10:09 AM
Signum Biosciences has entered into an agreement with GlaxoSmithKline to collaborate on Signum's phosphatase screening technology and Phosphoprotein Phosphatase 2A (PP2A). The agreement provides Signum with research support and milestone payments. GSK receives the exclusive right of Signum's proprietary phosphatase screening technology for GSK's research and development activities in neurosciences.
 
GSK and Signum will undertake a broad R&D collaboration to screen and identify PP2A targeted compounds including those bridging the link between PP2A methylation and tau hyperphosphorylation. 
 
Maxwell Stock, president of Signum Biosciences, commented, "GSK is an ideal partner for Signum.  We will develop therapeutics using our phosphatase screening technology in an alliance that utilizes the expertise of both companies.  We are proud to be working in collaboration with a leading pharmaceutical company in innovative research and development.  Collaborations such as these allow partners to share knowledge, expertise and resources and thereby provide a highly effective way of progressing cutting edge research and developing an effective drug." 
Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.